BioNTech is acquiring Chinese biotech Biotheus for $800 million upfront plus $150 million in milestones, gaining multiple ...

Sy­ros Phar­ma­ceu­ti­cals’ share price nose­dived af­ter its last drug can­di­date flunked a tri­al in hema­to­log­i­cal ...

Pfizer, reportedly working with Goldman Sachs, is considering selling its hospital drugs unit while facing pressure from ...

AstraZeneca CEO Pascal Soriot affirms commitment to China despite investigation involving China president Leon Wang and other employees. Wang, who reported directly to Soriot, and former AstraZeneca ...

Syndax Pharmaceuticals' experimental drug revumenib achieved 23% complete remission in NPM1-mutated acute myeloid leukemia ...

Merck and AstraZeneca's MEK inhibitor Koselugo (selumetinib) showed significant improvement in adult neurofibromatosis type 1 ...

Merck KGaA's pimicotinib met its primary endpoint in Phase 3 MANEUVER trial for tenosynovial giant cell tumors, showing 54% ...

Apollo Therapeutics will pay $12M upfront and up to $926M in milestone payments to Sunshine Lake Pharma for worldwide rights (excluding China) to their FGF21/GLP-1 dual receptor agonist ...

Diverge, a startup helping Medicaid members access care, raised $52 million led by Alphabet's GV. The company, launched in ...

Bayer CEO Bill Anderson affirmed plans to manage Xarelto's generic competition decline, as shares hit record low following Q3 ...

AstraZeneca announces $2 billion investment to create 1,000 new US jobs, adding to previous $1.5 billion commitment. The $3.5 ...

Roche is aligning with Flare Therapeutics to work on small molecules for cancer by going after transcription factor targets, ...